Universe Pharmaceuticals Stock Surges 125%, With A 6-Day Winning Spree
Universe Pharmaceuticals (UPC) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 125% return. The company has gained about $NaN in value over the last 6 days, with its current market capitalization at about $NaN. The stock remains 61.2% below its value at the end of 2024. This compares with year-to-date returns of 14.8% for the S&P 500.
UPC provides traditional Chinese medicine derivatives and third-party biomedical drugs, medical instruments, and supplements for treating chronic elderly conditions, promoting physical wellness and longevity in China.
If you seek an upside with less volatility than holding an individual stock, consider the High Quality Portfolio (HQ) – HQ has outperformed its benchmark – a combination of S&P 500, Russell, and S&P midcap index, and achieved returns exceeding 91% since its inception. Risk management is key – consider, what could long-term portfolio performance be if you blended 10% commodities, 10% gold, and 2% crypto with HQ’s performance metrics.
Comparing UPC Stock Returns With The S&P 500
The following table summarizes the return for UPC stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | UPC | S&P 500 |
|---|---|---|
| 1D | 83.0% | 0.6% |
| 6D (Current Streak) | 125.2% | 1.0% |
| 1M (21D) | 136.5% | 3.7% |
| 3M (63D) | 150.9% | 7.5% |
| YTD 2025 | -61.2% | 14.8% |
| 2024 | -98.0% | 23.3% |
| 2023 | -76.9% | 24.2% |
| 2022 | -11.3% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 51 S&P constituents with 3 days or more of consecutive gains and 78 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 21 | 45 |
| 4D | 15 | 19 |
| 5D | 9 | 7 |
| 6D | 2 | 2 |
| 7D or more | 4 | 5 |
| Total >=3 D | 51 | 78 |
Key Financials for Universe Pharmaceuticals (UPC)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $32.3 Mil | $23.0 Mil |
| Operating Income | $-4.0 Mil | $-8.0 Mil |
| Net Income | $-6.6 Mil | $-8.7 Mil |
Last 2 Fiscal Quarters:
| Metric | – |
|---|---|
| Revenues | $- |
| Operating Income | $- |
| Net Income | $- |
While UPC stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.